Track topics on Twitter Track topics that are important to you
Swiss drug major Novartis AG (NVS) said that the U.S. Food and Drug Administration or FDA has approved a label update for Cosentyx or secukinumab, the first interleukin-17A or IL-17A inhibitor approved to treat moderate-to-severe plaque psoriasis.
Original Article: Novartis Gets FDA Approval For Cosentyx Label Update - Quick FactsNEXT ARTICLE
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...